Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Inclusion Criteria * Signed Written Informed Consent * Subjects must have received at least one dose of Asunaprevir and/or Daclatasvir * Subjects participating in Daclatasvir and/or Asunaprevir studies (ie, protocol numbers beginning with AI443, AI444 or AI447) may enroll regardless of virologic response * Completed the required post-treatment follow-up period in previous study * Must enroll in this study within 6 months of completing previous BMS study or within 6 months of protocol availability at the clinical site * Men and women, ages 18 and older Exclusion Criteria: * Subject must not have been treated with any antiviral or immunomodulatory drug for chronic hepatitis C (CHC) after completion of the previous study during which Asunaprevir and/or Daclatasvir were administered * Subject must not be participating in any other trial, excluding non-interventional trials * Prisoners or subjects who are involuntarily incarcerated * Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness